Emmaus Life Sciences, Inc.
EMMA
$0.01
$0.000.99%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.01% | -38.34% | -47.61% | -3.99% | -53.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.01% | -38.34% | -47.61% | -3.99% | -53.42% |
| Cost of Revenue | -23.95% | -37.31% | -37.76% | -12.45% | 61.78% |
| Gross Profit | 21.25% | -38.41% | -48.07% | -3.02% | -56.62% |
| SG&A Expenses | -6.45% | -53.79% | -31.68% | -37.89% | -36.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.38% | -52.77% | -33.53% | -35.46% | -32.62% |
| Operating Income | 172.26% | 43.54% | -163.57% | 64.23% | -141.11% |
| Income Before Tax | -11.08% | -181.98% | 19.88% | 46.59% | -258.80% |
| Income Tax Expenses | 166.67% | 58,000.00% | -2,003.23% | 157.14% | 105.36% |
| Earnings from Continuing Operations | -11.61% | -213.63% | 48.03% | 46.41% | -244.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.61% | -213.63% | 48.03% | 46.41% | -244.58% |
| EBIT | 172.26% | 43.54% | -163.57% | 64.23% | -141.11% |
| EBITDA | 175.63% | 44.49% | -162.24% | 64.34% | -140.56% |
| EPS Basic | -10.22% | -213.64% | 48.41% | 48.08% | -225.11% |
| Normalized Basic EPS | -47.65% | -139.11% | -13.21% | 61.03% | -218.06% |
| EPS Diluted | -10.22% | -213.64% | 48.41% | 48.08% | -253.93% |
| Normalized Diluted EPS | -47.65% | -139.11% | -13.21% | 61.03% | -218.06% |
| Average Basic Shares Outstanding | 1.09% | 0.00% | 0.81% | 3.27% | 15.74% |
| Average Diluted Shares Outstanding | 1.09% | 0.00% | 0.81% | 3.27% | 15.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |